Evidence map›Paper›PMID 25574399›Full record

ArticleJournal of drug delivery2014

Tumor angiogenesis therapy using targeted delivery of Paclitaxel to the vasculature of breast cancer metastases.

Shijun Zhu, Walter Kisiel, Yang J Lu, Lars C Petersen, John M Ndungu, Terry W Moore, Ernest T Parker, Aiming Sun, Dennis C Liotta, Bassel F El-Rayes and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of drug delivery, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Shijun ZhuDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, 1365 Clifton Road, NE, Atlanta, GA 30322, USA.ORCID 0000-0003-1257-6528
Walter KisielDepartment of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Yang J LuDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, 1365 Clifton Road, NE, Atlanta, GA 30322, USA.
Lars C PetersenBiopharmaceuticals Research Unit, Novo Nordisk A/S, 2760 Måløv, Denmark.
John M NdunguDepartment of Chemistry, Emory University, 1515 Dickey Drive, Atlanta, GA 30322, USA.
Terry W MooreDepartment of Medicinal Chemistry and Pharmacognosy and UIC Cancer Center, University of Illinois at Chicago, Chicago, IL 60612, USA.
Ernest T ParkerDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, 1365 Clifton Road, NE, Atlanta, GA 30322, USA.
Aiming SunDepartment of Chemistry, Emory University, 1515 Dickey Drive, Atlanta, GA 30322, USA.
Dennis C LiottaDepartment of Chemistry, Emory University, 1515 Dickey Drive, Atlanta, GA 30322, USA.
Bassel F El-RayesDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, 1365 Clifton Road, NE, Atlanta, GA 30322, USA.
Daniel J BratDepartment of Pathology, Winship Cancer Institute, Emory University, 1365 Clifton Road, NE, Atlanta, GA 30322, USA.
James P SnyderDepartment of Chemistry, Emory University, 1515 Dickey Drive, Atlanta, GA 30322, USA.
Mamoru ShojiDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, 1365 Clifton Road, NE, Atlanta, GA 30322, USA.
Emory University · USNovo Nordisk (Denmark) · DKUniversity of Illinois Chicago · USUniversity of New Mexico · US

Funding

Targeted Delivery of a Novel Synthetic Curcumin Analog, EF24 to Glioblastoma andR21CA139035 · NCI · EMORY UNIVERSITY · PI BRAT, DANIEL J, SHOJI, MAMORU NONE · 2011 to 2012
$371k
NCI NIH HHS R21 CA139035
6 · The paper itself

Abstract

Breast cancer aberrantly expresses tissue factor (TF) in cancer tissues and cancer vascular endothelial cells (VECs). TF plays a central role in cancer angiogenesis, growth, and metastasis and, as such, is a target for therapy and drug delivery. TF is the cognate receptor of factor VIIa (fVIIa). We have coupled PTX (paclitaxel, also named Taxol) with a tripeptide, phenylalanine-phenylalanine-arginine chloromethyl ketone (FFRck) and conjugated it with fVIIa. The key aim of the work is to evaluate the antiangiogenic effects of PTX-FFRck-fVIIa against a PTX-resistant breast cancer cell line. Matrigel mixed with VEGF and MDA-231 was injected subcutaneously into the flank of athymic nude mice. Animals were treated by tail vein injection of the PTX-FFRck-fVIIa conjugate, unconjugated PTX, or PBS. The PTX-FFRck-fVIIa conjugate significantly reduces microvessel density in matrigel (p < 0.01-0.05) compared to PBS and unconjugated PTX. The breast cancer lung metastasis model in athymic nude mice was developed by intravenous injection of MDA-231 cells expressing luciferase. Animals were similarly treated intravenously with the PTX-FFRck-fVIIa conjugate or PBS. The conjugate significantly inhibits lung metastasis as compared to the control, highlighting its potential to antagonize angiogenesis in metastatic carcinoma. In conclusion, PTX conjugated to fVIIa is a promising therapeutic approach for improving selective drug delivery and inhibiting angiogenesis.

Identifiers

PMID25574399
PMCPMC4273585
OpenAlexW2040217907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.